For researchers submitting trial data to ClinicalTrials.gov, the Adverse Events module is one of four mandatory results sections. It requires reporting in three primary categories: All-Cause Mortality: A table tracking all deaths that occurred during the study, regardless of cause. Serious Adverse Events (SAEs): A tabular summary of events resulting in death, life-threatening conditions, hospitalization, or significant disability. Other Adverse Events: A table for non-serious events that exceed a specific frequency threshold, such as 5% within any study arm.
Adverse Events Module path is as follows:
Study -> Results Section -> Adverse Events Module -> Event Groups
Study -> Results Section -> Adverse Events Module -> Serious Events
Study -> Results Section -> Adverse Events Module -> Other Events
| Title | Description | Deaths # Affected | Deaths # At Risk | Serious # Affected | Serious # At Risk | Other # Affected | Other # At Risk | View |
|---|---|---|---|---|---|---|---|---|
| 1A: Healthy, 2.5 mg/kg | SARS-CoV-2-uninfected volunteers will receive a single intravenous infusion of DZIF-10c at a dose of 2.5 mg/kg DZIF-10c: SARS-CoV-2-neutralizing monoclonal antibody DZIF-10c by intravenous infusion | 0 | None | 0 | 3 | 2 | 3 | View |
| 1B: Healthy, 10 mg/kg | SARS-CoV-2-uninfected volunteers will receive a single intravenous infusion of DZIF-10c at a dose of 10 mg/kg DZIF-10c: SARS-CoV-2-neutralizing monoclonal antibody DZIF-10c by intravenous infusion | 0 | None | 0 | 3 | 1 | 3 | View |
| 2C: Infected, 40 mg/kg | SARS-CoV-2-infected volunteers will receive a single intravenous infusion of DZIF-10c at a dose of 40 mg/kg DZIF-10c: SARS-CoV-2-neutralizing monoclonal antibody DZIF-10c by intravenous infusion | 0 | None | 0 | 3 | 1 | 3 | View |
| 2D: Infected, 40 mg/kg | SARS-CoV-2-infected volunteers randomized to receive an intravenous infusion of DZIF-10c at a dose of 40 mg/kg (blinded) DZIF-10c: SARS-CoV-2-neutralizing monoclonal antibody DZIF-10c by intravenous infusion | 0 | None | 0 | 26 | 18 | 26 | View |
| 2D: Infected, Placebo | SARS-CoV-2-infected volunteers randomized to receive an intravenous infusion of placebo (blinded) Placebo: Sterile normal saline | 0 | None | 0 | 13 | 10 | 13 | View |
| 1C: Healthy, 40 mg/kg | SARS-CoV-2-uninfected volunteers will receive a single intravenous infusion of DZIF-10c at a dose of 40 mg/kg DZIF-10c: SARS-CoV-2-neutralizing monoclonal antibody DZIF-10c by intravenous infusion | 0 | None | 0 | 3 | 2 | 3 | View |
| 1D: Healthy, 80 mg/kg | SARS-CoV-2-uninfected volunteers will receive a single intravenous infusion of DZIF-10c at a dose higher than 40 mg/kg DZIF-10c: SARS-CoV-2-neutralizing monoclonal antibody DZIF-10c by intravenous infusion | 0 | None | 0 | 6 | 0 | 6 | View |
| Term | Type | Organ System | Vocab | View |
|---|---|---|---|---|
| Chest discomfort | SYSTEMATIC_ASSESSMENT | General disorders | None | View |
| Fatigue | SYSTEMATIC_ASSESSMENT | General disorders | None | View |
| Non-cardiac chest pain | SYSTEMATIC_ASSESSMENT | General disorders | None | View |
| Pyrexia | SYSTEMATIC_ASSESSMENT | General disorders | None | View |
| Malaise | SYSTEMATIC_ASSESSMENT | General disorders | None | View |
| Vertigo | SYSTEMATIC_ASSESSMENT | Ear and labyrinth disorders | None | View |
| Pain | SYSTEMATIC_ASSESSMENT | General disorders | None | View |
| Flushing | SYSTEMATIC_ASSESSMENT | Vascular disorders | None | View |
| Hypertension | SYSTEMATIC_ASSESSMENT | Vascular disorders | None | View |
| Oropharyngeal pain | SYSTEMATIC_ASSESSMENT | Respiratory, thoracic and mediastinal disorders | None | View |
| Cough | SYSTEMATIC_ASSESSMENT | Respiratory, thoracic and mediastinal disorders | None | View |
| Dyspnoea | SYSTEMATIC_ASSESSMENT | Respiratory, thoracic and mediastinal disorders | None | View |
| Anaemia | SYSTEMATIC_ASSESSMENT | Blood and lymphatic system disorders | None | View |
| Neutropenia | SYSTEMATIC_ASSESSMENT | Blood and lymphatic system disorders | None | View |
| Headache | SYSTEMATIC_ASSESSMENT | Nervous system disorders | None | View |
| Hyposmia | SYSTEMATIC_ASSESSMENT | Nervous system disorders | None | View |
| Dysgeusia | SYSTEMATIC_ASSESSMENT | Nervous system disorders | None | View |
| Disturbance in attention | SYSTEMATIC_ASSESSMENT | Nervous system disorders | None | View |
| Hypogeusia | SYSTEMATIC_ASSESSMENT | Nervous system disorders | None | View |
| Parosmia | SYSTEMATIC_ASSESSMENT | Nervous system disorders | None | View |
| Ageusia | SYSTEMATIC_ASSESSMENT | Nervous system disorders | None | View |
| Tympanic membrane perforation | SYSTEMATIC_ASSESSMENT | Ear and labyrinth disorders | None | View |
| Dyspepsia | SYSTEMATIC_ASSESSMENT | Gastrointestinal disorders | None | View |
| Proctalgia | SYSTEMATIC_ASSESSMENT | Gastrointestinal disorders | None | View |
| Gastrooesophageal reflux disease | SYSTEMATIC_ASSESSMENT | Gastrointestinal disorders | None | View |
| Nausea | SYSTEMATIC_ASSESSMENT | Gastrointestinal disorders | None | View |
| Vomiting | SYSTEMATIC_ASSESSMENT | Gastrointestinal disorders | None | View |
| Rash | SYSTEMATIC_ASSESSMENT | Skin and subcutaneous tissue disorders | None | View |
| Pruritus | SYSTEMATIC_ASSESSMENT | Skin and subcutaneous tissue disorders | None | View |
| Myalgia | SYSTEMATIC_ASSESSMENT | Musculoskeletal and connective tissue disorders | None | View |
| Arthralgia | SYSTEMATIC_ASSESSMENT | Musculoskeletal and connective tissue disorders | None | View |
| Thyroid mass | SYSTEMATIC_ASSESSMENT | Endocrine disorders | None | View |
| COVID-19 | SYSTEMATIC_ASSESSMENT | Infections and infestations | None | View |
| Rhinitis | SYSTEMATIC_ASSESSMENT | Infections and infestations | None | View |
| Cystitis | SYSTEMATIC_ASSESSMENT | Infections and infestations | None | View |
| Tonsillitis | SYSTEMATIC_ASSESSMENT | Infections and infestations | None | View |
| Tooth abscess | SYSTEMATIC_ASSESSMENT | Infections and infestations | None | View |
| Palpitations | SYSTEMATIC_ASSESSMENT | Cardiac disorders | None | View |